This is a non-financial pipeline catalyst that supports the radiopharmaceutical thesis but does not alter near-term fundamentals. Monitor for FDA meeting minutes or pivotal trial initiation for LNTH-2513; no immediate trading catalyst.
Price Chart
Executive Summary
Lantheus announced that an image from its LNTH-2513 (18F-GP1) PET/CT trial for deep vein thrombosis (DVT) was awarded SNMMI's Image of the Year, with Phase 2 data showing 95% sensitivity and 92% specificity for proximal DVT. This is a non-financial pipeline milestone that validates the platform's potential in thromboembolic imaging but does not change near-term revenue or earnings.
Key Facts
- LNTH-2513 (18F-GP1) PET/CT awarded SNMMI 2026 Image of the Year for DVT detection.
- Investigator-initiated trial (n=46) showed 95% sensitivity and 92% specificity for proximal DVT vs venous ultrasonography.
- LNTH-2513 identified concomitant pulmonary embolism in 22 of 46 patients.
- No drug-related adverse events reported; well-tolerated.
- LNTH-2513 is an investigational agent; no regulatory submission or commercial timeline provided.
Financial Impact
No financial impact disclosed; LNTH-2513 is pre-commercial with no revenue contribution.
Risk Factors
- LNTH-2513 remains investigational; regulatory approval and commercial launch are uncertain.
- Competing imaging modalities (e.g., ultrasound, CT angiography) are well-established for DVT.
- No timeline for pivotal trial or FDA submission provided.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305065 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $100.10 $99.80 | ▼ −0.30% | ▲ +0.22% | $100.13 (+0.03%) |
Oct 2, 2026 24d ago | DEFA14A | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.13 (−0.06%) |
Oct 2, 2026 24d ago | 8-K | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.13 (−0.06%) |
Sep 16, 2026 5w ago | DEFA14A | $100.80 $100.55 | ▼ −0.25% | ▼ −0.38% | $100.13 (−0.66%) |
Aug 26, 2026 8w ago | PREM14A | $100.82 $100.47 | ▼ −0.35% | ▼ −1.00% | $100.13 (−0.68%) |
Aug 14, 2026 10w ago | Press Release | $100.95 $100.91 | ▼ −0.04% | ▲ +0.43% | $100.13 (−0.81%) |
Aug 6, 2026 11w ago | 8-K | $101.07 $100.95 | ▼ −0.12% | ▼ −0.73% | $100.13 (−0.93%) |
Aug 3, 2026 12w ago | 8-K / DEFA14A | $101.11 $101.50 | ▲ +0.39% | ▲ +0.59% | $100.13 (−0.97%) |
Aug 3, 2026 12w ago | DEFA14A / 8-K | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.13 (−1.05%) |
Aug 3, 2026 12w ago | Press Release | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.13 (−1.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers